Orchid Pharma has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg. Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.
Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.